Autors:

CiteWeb id: 20090000077

CiteWeb score: 5385

DOI: 10.1056/NEJMoa012843

Background The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris. Methods We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in native coronary arteries. The trial included 238 patients at 19 medical centers. The primary end point was in-stent late luminal loss (the difference between the minimal luminal diameter immediately after the procedure and the diameter at six months). Secondary end points included the percentage of in-stent stenosis of the luminal diameter and the rate of restenosis (luminal narrowing of 50 percent or more). We also analyzed a composite clinical end point consisting of death, myocardial infarction, and percutaneous or surgic...

The publication "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Medicine it is included to the Top 1000. Additionally, the publicaiton "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization" is placed in the Top 100 among other scientific works published in 2009.
Links to full text of the publication: